{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T21:53:49Z","timestamp":1763330029276,"version":"3.41.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Radiol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Due to a lack of data, there is an ongoing debate regarding the optimal frontline interventional therapy for unresectable hepatocellular carcinoma (HCC). The aim of the study is to compare the results of transarterial radioembolization (TARE) as the first-line therapy and as a subsequent therapy following prior transarterial chemoembolization (TACE) in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 83 patients were evaluated, with 38 patients having undergone at least one TACE session prior to TARE [27 male; mean age 67.2 years; 68.4% stage Barcelona clinic liver cancer (BCLC) B, 31.6% BCLC C]; 45 patients underwent primary TARE (33 male; mean age 69.9 years; 40% BCLC B, 58% BCLC C). Clinical [age, gender, BCLC stage, activity in gigabecquerel (GBq), Child\u2013Pugh status, portal vein thrombosis, tumor volume] and procedural [overall survival (OS), local tumor control (LTC), and progression-free survival (PFS)] data were compared. A regression analysis was performed to evaluate OS, LTC, and PFS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No differences were found in OS (95% CI: 1.12, <jats:italic>P\u2009<\/jats:italic>=\u20090.289), LTC (95% CI: 0.003, <jats:italic>P\u2009<\/jats:italic>=\u20090.95), and PFS (95% CI: 0.4, <jats:italic>P\u2009<\/jats:italic>=\u20090.525). The regression analysis revealed a relationship between Child\u2013Pugh score (<jats:italic>P\u2009<\/jats:italic>=\u20090.005), size of HCC lesions (&amp;gt;10\u2005cm) (<jats:italic>P\u2009<\/jats:italic>=\u20090.022), and OS; neither prior TACE (Child\u2013Pugh B patients; 95% CI: 0.120, <jats:italic>P\u2009<\/jats:italic>=\u20090.729) nor number of lesions (&amp;gt;10; 95% CI: 2.930, <jats:italic>P\u2009<\/jats:italic>=\u20090.087) correlated with OS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Prior TACE does not affect the outcome of TARE in unresectable HCC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fradi.2024.1346550","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T04:57:34Z","timestamp":1708405054000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcome of transarterial radioembolization in patients with hepatocellular carcinoma as a first-line interventional therapy and after a previous transarterial chemoembolization"],"prefix":"10.3389","volume":"4","author":[{"given":"Julia","family":"Wagenpfeil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick Arthur","family":"Kupczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Bruners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Siepmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emelie","family":"Guendel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian Alexander","family":"Luetkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Isaak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Kuetting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus Christian","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike Irmgard","family":"Attenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kuetting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0227475","article-title":"Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: a systematic review","volume":"15","author":"Yang","year":"2020","journal-title":"PLoS One"},{"key":"B2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"European Association for the study of the liver. EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.dld.2013.03.004","article-title":"Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study","volume":"45","author":"Sacco","year":"2013","journal-title":"Dig Liver Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/jso.27545","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: a review of current clinical trials","volume":"129","author":"Gamboa","year":"2024","journal-title":"J Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000464282","article-title":"Current standard and future perspectives in non-surgical therapy for hepatocellular carcinoma","volume":"96","author":"Eggert","year":"2017","journal-title":"Digestion"},{"key":"B8","doi-asserted-by":"publisher","first-page":"10327","DOI":"10.3748\/wjg.v21.i36.10327","article-title":"Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system","volume":"21","author":"Han","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/0284185120926474","article-title":"Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma","volume":"62","author":"Auer","year":"2021","journal-title":"Acta Radiol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s00270-014-1012-0","article-title":"Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma","volume":"38","author":"Pitton","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5009\/gnl19197","article-title":"The modified response evaluation criteria in solid tumors (RECIST) yield a more accurate prognoses than the RECIST 1.1 in hepatocellular carcinoma treated with transarterial radioembolization","volume":"6","author":"Lee","year":"2020","journal-title":"Gut Liver"},{"key":"B12","doi-asserted-by":"publisher","first-page":"742","DOI":"10.2214\/AJR.15.14802","article-title":"Transarterial chemoembolization and (90)Y radioembolization for hepatocellular carcinoma: review of current applications beyond intermediate-stage disease","volume":"205","author":"Fidelman","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/liv.12750","article-title":"Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma","volume":"35","author":"Kolligs","year":"2015","journal-title":"Liver Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s00270-012-0481-2","article-title":"Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma","volume":"36","author":"Moreno-Luna","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00270-022-03072-8","article-title":"TARE in hepatocellular carcinoma: from the right to the left of BCLC","volume":"45","author":"Guiu","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"7315","DOI":"10.2147\/OTT.S175715","article-title":"Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials","volume":"11","author":"Casadei Gardini","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3390\/cancers12040791","article-title":"Embolotherapeutic strategies for hepatocellular carcinoma: 2020 update","volume":"12","author":"Kishore","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.jvir.2011.08.013","article-title":"Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma","volume":"22","author":"Lance","year":"2011","journal-title":"J Vasc Interv Radiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","article-title":"Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma","volume":"140","author":"Salem","year":"2011","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/JHC.S224471","article-title":"Angiogenesis in hepatocellular carcinoma; pathophysiology, targeted therapy, and role of imaging","volume":"7","author":"Moawad","year":"2020","journal-title":"J Hepatocell Carcinoma"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.cgh.2013.04.028","article-title":"Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization","volume":"11","author":"Salem","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.3390\/cancers12071914","article-title":"Locoregional therapy approaches for hepatocellular carcinoma: recent advances and management strategies","volume":"12","author":"Makary","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12876-021-01805-6","article-title":"Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma","volume":"21","author":"Van Thai","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1080\/02656736.2018.1462536","article-title":"Microwave ablation with chemoembolization for large hepatocellular carcinoma in patients with cirrhosis","volume":"34","author":"Hu","year":"2018","journal-title":"Int J Hyperthermia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17483","DOI":"10.3748\/wjg.v20.i46.17483","article-title":"Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma","volume":"20","author":"Ni","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3109\/02656736.2011.605099","article-title":"MWA combined with TACE as a combined therapy for unresectable large-sized hepatocellular carcinoma","volume":"27","author":"Liu","year":"2011","journal-title":"Int J Hyperthermia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1053\/j.gastro.2017.02.039","article-title":"Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells in vitro and in mice by inhibiting cell division cycle 37 signaling","volume":"152","author":"Chen","year":"2017","journal-title":"Gastroenterology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/jnci\/djn134","article-title":"Design and endpoints of clinical trials in hepatocellular carcinoma","volume":"100","author":"Llovet","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"B29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1148\/radiol.2020191606","article-title":"Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study","volume":"296","author":"Hermann","year":"2020","journal-title":"Radiology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"101946","DOI":"10.1016\/j.ctrv.2019.101946","article-title":"Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma","volume":"82","author":"Vogel","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100633","DOI":"10.1016\/j.jhepr.2022.100633","article-title":"Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: results from the prospective CIRT study","volume":"5","author":"Kolligs","year":"2022","journal-title":"JHEP Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1148\/rg.2021210014","article-title":"Evolution of radioembolization in treatment of hepatocellular carcinoma: a pictorial review","volume":"41","author":"Miller","year":"2021","journal-title":"Radiographics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1148\/radiol.13130498","article-title":"Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization","volume":"270","author":"Yu","year":"2014","journal-title":"Radiology"}],"container-title":["Frontiers in Radiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fradi.2024.1346550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T04:57:36Z","timestamp":1708405056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fradi.2024.1346550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":35,"alternative-id":["10.3389\/fradi.2024.1346550"],"URL":"https:\/\/doi.org\/10.3389\/fradi.2024.1346550","relation":{},"ISSN":["2673-8740"],"issn-type":[{"type":"electronic","value":"2673-8740"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"article-number":"1346550"}}